(Q37022459)

17 August 2017

1 reference

title

Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology (English)

1 reference

17 August 2017

1 reference

Laura Biganzoli

3

0 references

Sharon H. Giordano

object named as

Sharon H Giordano

14

0 references

Chantal Bernard-Marty

6

object named as

Chantal Bernard-Marty

1 reference

17 August 2017

15

Hyman Muss

1 reference

17 August 2017

7

Arti Hurria

1 reference

17 August 2017

8

Martine Extermann

1 reference

17 August 2017

1

Hans Wildiers

1 reference

17 August 2017

Ian Kunkler

2

1 reference

17 August 2017

Jacques Fracheboud

4

1 reference

17 August 2017

George Vlastos

5

1 reference

17 August 2017

Véronique Girre

9

1 reference

17 August 2017

Etienne Brain

10

1 reference

17 August 2017

Riccardo A Audisio

11

1 reference

17 August 2017

Harry Bartelink

12

1 reference

17 August 2017

Mary Barton

13

1 reference

17 August 2017

Matti Aapro

16

1 reference

17 August 2017

publication date

1 December 2007

1 reference

Lancet Oncology Commission

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1101-1115

1 reference

Global trends in breast cancer incidence and mortality 1973-1997.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Tumor characteristics and clinical outcome of elderly women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

The natural history of breast carcinoma in the elderly: implications for screening and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Factors associated with surgical and radiation therapy for early stage breast cancer in older women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Radiation therapy and patient age in the survival from early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Association between age and the utilization of radiotherapy in Ontario

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Undertreatment strongly decreases prognosis of breast cancer in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Breast cancer treatment guidelines in older women.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Cancer treatment protocols. Who gets chosen?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Barriers to clinical trial participation by older women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Cancer screening in elderly patients: a framework for individualized decision making

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Aging, comorbidity, and breast cancer survival: an epidemiologic view

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Long-term effects of mammography screening: updated overview of the Swedish randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Routine screening mammography in women older than 74 years: a review of the available data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Seventy-five years is an appropriate upper age limit for population-based mammography screening

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

American Cancer Society guidelines for the early detection of cancer, 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Sentinel node biopsy in elderly breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

The surgical risk of elderly patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Management of elderly patients with breast cancer: the time for surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Treatment of breast cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Factors influencing treatment patterns of breast cancer patients age 75 and older

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Breast conservation or mastectomy: treatment choice of women aged 70 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

The number of positive margins influences the outcome of women treated with breast preservation for early stage breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

The importance of the lumpectomy surgical margin status in long-term results of breast conservation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Treatment of elderly breast cancer patients in a community hospital setting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Physical and psychological morbidity after axillary lymph node dissection for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Factors influencing arm and axillary symptoms after treatment for node negative breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

The sentinel node in breast cancer--a multicenter validation study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Is breast cancer sentinel lymph node mapping valuable for patients in their seventies and beyond?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Breast irradiation in the older woman: a toxicity study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Randomized Clinical Trial to Assess the Effectiveness of Breast Irradiation Following Lumpectomy and Axillary Disection for Node-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Radiotherapy after breast-preserving surgery in women with localized cancer of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Effectiveness of Radiation Therapy for Older Women With Early Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Hypofractionated radiation therapy in breast cancer: a revolutionary breakthrough or a long way to go?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Postmastectomy Radiation and Survival in Older Women With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Consensus Statement on postmastectomy radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Does aggressive local therapy improve survival in metastatic breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Pharmacology of Anticancer Drugs in the Elderly Population

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

Safety of long-term administration of bisphosphonates in elderly cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970378-9

7 January 2021

10.1016/S1470-2045(07)70378-9

Identifiers

DOI

1 reference

release_n6xd4rwdbresdiftcmoqkcmlry

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n6xd4rwdbresdiftcmoqkcmlry

24 November 2022

mapped directly with Wikidata item

1 reference